Prelude Therapeutics Inc PRLD.OQ PRLD.O is expected to show no change in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 47 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.9% in the last three months.
Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50, above its last closing price of $0.92.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.46 | -0.38 | Beat | 18 | |
Sep. 30 2024 | -0.47 | -0.47 | -0.43 | Beat | 8.9 |
Jun. 30 2024 | -0.43 | -0.43 | -0.46 | Missed | -7 |
Mar. 31 2024 | -0.48 | -0.48 | -0.42 | Beat | 13.4 |
Dec. 31 2023 | -0.49 | -0.49 | -0.46 | Beat | 6.1 |
Sep. 30 2023 | -0.58 | -0.58 | -0.45 | Beat | 22.7 |
Jun. 30 2023 | -0.64 | -0.63 | -0.54 | Beat | 14.7 |
Mar. 31 2023 | -0.69 | -0.68 | -0.58 | Beat | 15.3 |
This summary was machine generated May 2 at 13:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)